The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab.
 
Edgar Gonzalez-Kozlova
No Relationships to Disclose
 
Hsin-Hui Huang
No Relationships to Disclose
 
Mary Weber Redman
No Relationships to Disclose
 
Roy S. Herbst
Leadership - Immunocore; Junshi Pharmaceuticals
Consulting or Advisory Role - Abbvie; ARMO Biosciences; AstraZeneca; Bayer; Biodesix; Bolt Biotherapeutics; Bristol-Myers Squibb; Candel Therapeutics; Checkpoint Therapeutics; Cybrexa Therapeutics; DynamiCure Biotechnology; eFFECTOR Therapeutics; EMD Serono; Foundation Medicine; Genentech/Roche; Genmab; Gilead/Forty Seven; Halozyme; Heat Biologics; HiberCell; I-Mab; Immune-Onc Therapeutics; Infinity Pharmaceuticals; Johnson and Johnson; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Ocean Biomedical; OncoCyte; Oncternal Therapeutics; Pfizer; Refactor Health; Ribon Therapeutics; Sanofi; Seagen; Shire; Spectrum Pharmaceuticals; STCube Pharmaceuticals Inc.; Symphogen; Takeda; TESARO; Tocagen; Ventana Medical Systems; WindMIL; Xencor
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
 
Scott N. Gettinger
Research Funding - ARIAD/Takeda (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck (Inst); NextCure (Inst)
 
Lyudmila Bazhenova
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - Bayer; BMSi; Boehringer Ingelheim; Daichi; Genentech/Roche; Johnson and Johnson; Merck; Mirati Therapeutics; neuvogen; Novartis; Novocure; ORCIC; Regeneron; Sanofi; Turning Point Therapeutics
 
Hui Xie
No Relationships to Disclose
 
Manishkumar Patel
No Relationships to Disclose
 
Kai Nie
No Relationships to Disclose
 
Jocelyn Harris
No Relationships to Disclose
 
Kimberly Argueta
No Relationships to Disclose
 
Ethan Cerami
No Relationships to Disclose
 
Joyce Hong
No Relationships to Disclose
 
Roshni Biswas
No Relationships to Disclose
 
Stephen Van Nostrand
No Relationships to Disclose
 
Karen Kelly
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Daiichi Sanko; Debiopharm Group; Eisai; EMD Serono; Genentech; Genmab; Janssen; Lilly; Novartis; Regeneron; Sanofi; Takeda; Targeted Oncology
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Meyers Squibb (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Regeneron (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - EMD Serono; Lilly; Novartis; Takeda
 
Radim Moravec
No Relationships to Disclose
 
Diane Del Valle
No Relationships to Disclose
 
Seunghee Kim-Schulze
No Relationships to Disclose
 
Sacha Gnjatic
No Relationships to Disclose